Pre-made Andecaliximab benchmark antibody ( Whole mAb, anti-MMP9/MMP-9 therapeutic antibody, Anti-CLG4B/GELB/MANDP2 Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-024

Pre-Made Andecaliximab biosimilar, Whole mAb, Anti-MMP9/MMP-9 Antibody: Anti-CLG4B/GELB/MANDP2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Andecaliximab (INN; development code GS-5745) is an experimental humanized monoclonal antibody designed for the treatment of cancer and inflammatory diseases.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-024-1mg 1mg 3090 30% 2163

Size: 1mg | 10mg | 100mg



Description

Products Name (INN Index) Pre-Made Andecaliximab biosimilar, Whole mAb, Anti-MMP9/MMP-9 Antibody: Anti-CLG4B/GELB/MANDP2 therapeutic antibody
INN Name Andecaliximab
TargetMMP-9
FormatWhole mAb
DerivationChimeric (Mouse/Human)
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusDiscontinued
100% SI Structure5th9:HL:IM:JN
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2016
Year Recommended2017
CompaniesGilead Sciences
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedChronic obstructive pulmonary disease;Crohn's disease;Cystic fibrosis;Rheumatoid arthritis;Ulcerative colitis;Gastric cancer;Solid tumours;Glioblastoma
Development Techna